The Manufacturers Life Insurance Company Invests $31.14 Million in Prestige Consumer Healthcare Inc. $PBH

The Manufacturers Life Insurance Company bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the second quarter, Holdings Channel reports. The institutional investor bought 658,659 shares of the company’s stock, valued at approximately $31,135,000.

Several other hedge funds also recently modified their holdings of PBH. AQR Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after buying an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Jane Street Group LLC boosted its holdings in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after acquiring an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
• Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
• Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
• Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Trading Down 1.7%

NYSE:PBH opened at $51.27 on Friday. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $71.07. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. The firm’s 50 day moving average is $50.11 and its 200 day moving average is $54.64. The stock has a market capitalization of $2.43 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same period in the prior year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare’s revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).